Lost Money in Sage Therapeutics, Inc.?
Sage Therapeutics, Inc. shares plummeted 60% after the company announced that its depression drug, SAGE-217, failed to perform better than a placebo in its Phase 3 trial. Gibbs Law Group is investigating a potential Sage Therapeutics Class Action Lawsuit on behalf of investors who lost money in Sage Therapeutics, Inc. (NASDAQ: SAGE) stock.
To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.
On December 5, 2019, Sage Therapeutics stock plummeted 60% after the company announced that its depression drug failed to hit a key mark. The drug, SAGE-217, had previously shown positive results when tested against major depressive disorder in earlier studies, but the effects of the drug seemed to taper off by the two-week mark of the Phase 3 trial. According to the Boston Business Journal, “the company’s second potential drug surprised investors by missing the mark in a Phase 3 clinical trial.”
Following this news, on December 5, 2019, Sage Therapeutics’ stock price dropped nearly 60% to $60.18 per share, causing harm to investors.
What Should Sage Therapeutics Investors Do?
If you invested in Sage Therapeutics, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether Sage Therapeutics, Inc. and certain of its officers and/or directors have violated federal securities laws.
About Gibbs Law Group
Gibbs Law Group represents individual and institutional investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Top Boutique Law Firms in California,” “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Top Class Action Attorneys Under 40,” “Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys Under 40.”
This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Sage Therapeutics Aktie jetzt für 4€ handeln - auf Smartbroker.de